Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
- DOI
- 10.1186/s13023-023-02937-6
- Published
- 2023-10-21
- Container
- Orphanet Journal of Rare Diseases
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s13023-023-02937-6,
title = {Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study},
author = {Aleš Linhart and Gabriela Dostálová and Kathy Nicholls and Michael L. West and Camilla Tøndel and Ana Jovanovic and Pilar Giraldo and Bojan Vujkovac and Tarekegn Geberhiwot and Einat Brill-Almon and Sari Alon and Raul Chertkoff and Rossana Rocco and Derralynn Hughes},
year = {2023},
journal = {Orphanet Journal of Rare Diseases},
doi = {10.1186/s13023-023-02937-6},
url = {https://doi.org/10.1186/s13023-023-02937-6}
}RIS
TY - JOUR TI - Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study AU - Aleš Linhart AU - Gabriela Dostálová AU - Kathy Nicholls AU - Michael L. West AU - Camilla Tøndel AU - Ana Jovanovic AU - Pilar Giraldo AU - Bojan Vujkovac AU - Tarekegn Geberhiwot AU - Einat Brill-Almon AU - Sari Alon AU - Raul Chertkoff AU - Rossana Rocco AU - Derralynn Hughes PY - 2023 JO - Orphanet Journal of Rare Diseases DO - 10.1186/s13023-023-02937-6 UR - https://doi.org/10.1186/s13023-023-02937-6 ER -
APA
Linhart, A., Dostálová, G., Nicholls, K., West, M. L., Tøndel, C., Jovanovic, A., Giraldo, P., Vujkovac, B., Geberhiwot, T., Brill-Almon, E., Alon, S., Chertkoff, R., Rocco, R., & Hughes, D. (2023). Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-023-02937-6
Source records
- crossref · retrieved 2026-09-26T07:01:59.154Z